Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 21;14(2):226.
doi: 10.3390/diagnostics14020226.

Exceptional Liver Transplant Indications: Unveiling the Uncommon Landscape

Teodor Cabel  1 , Cristina Madalina Pascu  2 , Catalin Stefan Ghenea  1 , Bogdan Florin Dumbrava  3 , Deniz Gunsahin  1 , Andreea Andrunache  2 , Livia-Marieta Negoita  1 , Afrodita Panaitescu  1 , Ecaterina Mihaela Rinja  1 , Christopher Pavel  1   4 , Oana-Mihaela Plotogea  1   4 , Madalina Stan-Ilie  1   4 , Vasile Sandru  1   4 , Mariana Mihaila  2
Affiliations
Review

Exceptional Liver Transplant Indications: Unveiling the Uncommon Landscape

Teodor Cabel et al. Diagnostics (Basel). .

Abstract

Liver transplantation represents the definitive intervention for various etiologies of liver failure and encompasses a spectrum of rare indications crucial to understanding the diverse landscape of end-stage liver disease, with significantly improved survival rates over the past three decades. Apart from commonly encountered liver transplant indications such as decompensated cirrhosis and liver cancer, several rare diseases can lead to transplantation. Recognition of these rare indications is essential, providing a lifeline to individuals facing complex liver disorders where conventional treatments fail. Collaborative efforts among healthcare experts lead not only to timely interventions but also to the continuous refinement of transplant protocols. This continued evolution in transplant medicine promises hope for those facing diverse and rare liver diseases, marking a paradigm shift in the landscape of liver disease management.

Keywords: end-stage liver disease (ESLD); liver disease management (LDM); liver transplantation (LT); rare indications (RI).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Galle P.R., Forner A., Llovet J.M., Mazzaferro V., Piscaglia F., Raoul J.-L., Schirmacher P., Vilgrain V. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. - DOI - PubMed
    1. Jackson W.E., Malamon J.S., Kaplan B., Saben J.L., Schold J.D., Pomposelli J.J., Pomfret E.A. Survival Benefit of Living-Donor Liver Transplant. JAMA Surg. 2022;10:926–932. doi: 10.1001/jamasurg.2022.3327. - DOI - PMC - PubMed
    1. Millson C., Considine A., Cramp M.E., Holt A., Hubscher S., Hutchinson J., Jones K., Leithead J., Masson S., Menon K., et al. Adult liver transplantation: A UK clinical guideline—Part 1: Pre-operation. Frontline Gastroenterol. 2020;5:375–384. doi: 10.1136/flgastro-2019-101215. - DOI - PMC - PubMed
    1. de Ville de Goyet J., Baumann U., Karam V., Adam R., Nadalin S., Heaton N., Reding R., Branchereau S., Mirza D., Klempnauer J.L., et al. European Liver, Intestine Transplant Association. European Liver Transplant Registry: Donor and transplant surgery aspects of 16,641 liver transplantations in children. Hepatology. 2022;3:634–645. doi: 10.1002/hep.32223. - DOI - PubMed
    1. Kwong A.J., Ebel N.H., Kim W.R., Lake J.R., Smith J.M., Schladt D.P., Skeans M.A., Foutz J., Gauntt K., Cafarella M., et al. OPTN/SRTR 2020 Annual Data Report: Liver. Am. J. Transpl. 2022;22((Suppl 2)):204–309. doi: 10.1111/ajt.16978. - DOI - PubMed

LinkOut - more resources